Study #2018-0527
A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2575 in Patients with Hematologic Malignancies
MD Anderson Study Status
Not Accepting
Treatment Agent
APG-2575
Description
This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
Information and next steps
Disease:
Hematologic Malignancies
Study phase:
I (Early)
Physician name:
Marina Konopleva
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.